CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.10303-10306 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10306 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 10303 |
| container_title | Blood |
| container_volume | 140 |
| creator | McGuirk, Joseph P. Tam, Constantine S. Kröger, Nicolaus Riedell, Peter A. Murthy, Hemant S. Ho, Phoebe Joy Maakaron, Joseph E. Waller, Edmund K. Awan, Farrukh T. Shaughnessy, Paul J. Ghobadi, Armin Bishop, Michael R. Alfonso-Pierola, Ana Dickinson, Michael Ramakrishnan Geethakumari, Praveen Ross, Ainsley Stevens, William Xu, Huansheng Ma, Anna Cohen, Sarah Beaussant Maziarz, Richard T. Bachier, Carlos |
| description | |
| doi_str_mv | 10.1182/blood-2022-166432 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_166432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122061900</els_id><sourcerecordid>S0006497122061900</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1852-f2ebb02ecaa479b21dde01af2a9d8e494fc4675f06988cb411412b6c8ab07aa13</originalsourceid><addsrcrecordid>eNp9kEGP0zAQhSMEEmXhB3CbY3sw6_GmaQKnrimwUiSqbJG4RRNn0hq5cWVnQf1v_DhcypnTe4f33oy-LHuL8h1iqW47530vlFRKYFHkd-pZNsOlKoWUSj7PZlLKQuTVCl9mr2L8ISWmzHKW_da774gS1s75PY9sDejm4XHbCE2xEptxb0fmwD3odQM70OxcBDvClibL4xRhvp3iAn7Z6QANOzrFlPUh-SGQmXw4w7y5bRZQU9gz3IvLAtTn4-ngjwTz-l7Xi_cpHp9cWhuCP8J0YNgeKDIgfPRJNtGQSwf9CJpCl-RxeurPr7MXA7nIb_7pTfbt02anv4j66-cHva6FwXKpxKC466RiQ5Svqk5h37NEGhRVfcl5lQ8mL1bLQRZVWZouR8xRdYUpqZMrIry7yfC6a4KPMfDQnoI9Uji3KNsL_vYv_vaCv73iT50P1w6nx35aDm00CZjh3gY2U9t7-5_2Hyx6i8o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>McGuirk, Joseph P. ; Tam, Constantine S. ; Kröger, Nicolaus ; Riedell, Peter A. ; Murthy, Hemant S. ; Ho, Phoebe Joy ; Maakaron, Joseph E. ; Waller, Edmund K. ; Awan, Farrukh T. ; Shaughnessy, Paul J. ; Ghobadi, Armin ; Bishop, Michael R. ; Alfonso-Pierola, Ana ; Dickinson, Michael ; Ramakrishnan Geethakumari, Praveen ; Ross, Ainsley ; Stevens, William ; Xu, Huansheng ; Ma, Anna ; Cohen, Sarah Beaussant ; Maziarz, Richard T. ; Bachier, Carlos</creator><creatorcontrib>McGuirk, Joseph P. ; Tam, Constantine S. ; Kröger, Nicolaus ; Riedell, Peter A. ; Murthy, Hemant S. ; Ho, Phoebe Joy ; Maakaron, Joseph E. ; Waller, Edmund K. ; Awan, Farrukh T. ; Shaughnessy, Paul J. ; Ghobadi, Armin ; Bishop, Michael R. ; Alfonso-Pierola, Ana ; Dickinson, Michael ; Ramakrishnan Geethakumari, Praveen ; Ross, Ainsley ; Stevens, William ; Xu, Huansheng ; Ma, Anna ; Cohen, Sarah Beaussant ; Maziarz, Richard T. ; Bachier, Carlos</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-166432</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.10303-10306</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1852-f2ebb02ecaa479b21dde01af2a9d8e494fc4675f06988cb411412b6c8ab07aa13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>McGuirk, Joseph P.</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><creatorcontrib>Kröger, Nicolaus</creatorcontrib><creatorcontrib>Riedell, Peter A.</creatorcontrib><creatorcontrib>Murthy, Hemant S.</creatorcontrib><creatorcontrib>Ho, Phoebe Joy</creatorcontrib><creatorcontrib>Maakaron, Joseph E.</creatorcontrib><creatorcontrib>Waller, Edmund K.</creatorcontrib><creatorcontrib>Awan, Farrukh T.</creatorcontrib><creatorcontrib>Shaughnessy, Paul J.</creatorcontrib><creatorcontrib>Ghobadi, Armin</creatorcontrib><creatorcontrib>Bishop, Michael R.</creatorcontrib><creatorcontrib>Alfonso-Pierola, Ana</creatorcontrib><creatorcontrib>Dickinson, Michael</creatorcontrib><creatorcontrib>Ramakrishnan Geethakumari, Praveen</creatorcontrib><creatorcontrib>Ross, Ainsley</creatorcontrib><creatorcontrib>Stevens, William</creatorcontrib><creatorcontrib>Xu, Huansheng</creatorcontrib><creatorcontrib>Ma, Anna</creatorcontrib><creatorcontrib>Cohen, Sarah Beaussant</creatorcontrib><creatorcontrib>Maziarz, Richard T.</creatorcontrib><creatorcontrib>Bachier, Carlos</creatorcontrib><title>CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kEGP0zAQhSMEEmXhB3CbY3sw6_GmaQKnrimwUiSqbJG4RRNn0hq5cWVnQf1v_DhcypnTe4f33oy-LHuL8h1iqW47530vlFRKYFHkd-pZNsOlKoWUSj7PZlLKQuTVCl9mr2L8ISWmzHKW_da774gS1s75PY9sDejm4XHbCE2xEptxb0fmwD3odQM70OxcBDvClibL4xRhvp3iAn7Z6QANOzrFlPUh-SGQmXw4w7y5bRZQU9gz3IvLAtTn4-ngjwTz-l7Xi_cpHp9cWhuCP8J0YNgeKDIgfPRJNtGQSwf9CJpCl-RxeurPr7MXA7nIb_7pTfbt02anv4j66-cHva6FwXKpxKC466RiQ5Svqk5h37NEGhRVfcl5lQ8mL1bLQRZVWZouR8xRdYUpqZMrIry7yfC6a4KPMfDQnoI9Uji3KNsL_vYv_vaCv73iT50P1w6nx35aDm00CZjh3gY2U9t7-5_2Hyx6i8o</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>McGuirk, Joseph P.</creator><creator>Tam, Constantine S.</creator><creator>Kröger, Nicolaus</creator><creator>Riedell, Peter A.</creator><creator>Murthy, Hemant S.</creator><creator>Ho, Phoebe Joy</creator><creator>Maakaron, Joseph E.</creator><creator>Waller, Edmund K.</creator><creator>Awan, Farrukh T.</creator><creator>Shaughnessy, Paul J.</creator><creator>Ghobadi, Armin</creator><creator>Bishop, Michael R.</creator><creator>Alfonso-Pierola, Ana</creator><creator>Dickinson, Michael</creator><creator>Ramakrishnan Geethakumari, Praveen</creator><creator>Ross, Ainsley</creator><creator>Stevens, William</creator><creator>Xu, Huansheng</creator><creator>Ma, Anna</creator><creator>Cohen, Sarah Beaussant</creator><creator>Maziarz, Richard T.</creator><creator>Bachier, Carlos</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study</title><author>McGuirk, Joseph P. ; Tam, Constantine S. ; Kröger, Nicolaus ; Riedell, Peter A. ; Murthy, Hemant S. ; Ho, Phoebe Joy ; Maakaron, Joseph E. ; Waller, Edmund K. ; Awan, Farrukh T. ; Shaughnessy, Paul J. ; Ghobadi, Armin ; Bishop, Michael R. ; Alfonso-Pierola, Ana ; Dickinson, Michael ; Ramakrishnan Geethakumari, Praveen ; Ross, Ainsley ; Stevens, William ; Xu, Huansheng ; Ma, Anna ; Cohen, Sarah Beaussant ; Maziarz, Richard T. ; Bachier, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1852-f2ebb02ecaa479b21dde01af2a9d8e494fc4675f06988cb411412b6c8ab07aa13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McGuirk, Joseph P.</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><creatorcontrib>Kröger, Nicolaus</creatorcontrib><creatorcontrib>Riedell, Peter A.</creatorcontrib><creatorcontrib>Murthy, Hemant S.</creatorcontrib><creatorcontrib>Ho, Phoebe Joy</creatorcontrib><creatorcontrib>Maakaron, Joseph E.</creatorcontrib><creatorcontrib>Waller, Edmund K.</creatorcontrib><creatorcontrib>Awan, Farrukh T.</creatorcontrib><creatorcontrib>Shaughnessy, Paul J.</creatorcontrib><creatorcontrib>Ghobadi, Armin</creatorcontrib><creatorcontrib>Bishop, Michael R.</creatorcontrib><creatorcontrib>Alfonso-Pierola, Ana</creatorcontrib><creatorcontrib>Dickinson, Michael</creatorcontrib><creatorcontrib>Ramakrishnan Geethakumari, Praveen</creatorcontrib><creatorcontrib>Ross, Ainsley</creatorcontrib><creatorcontrib>Stevens, William</creatorcontrib><creatorcontrib>Xu, Huansheng</creatorcontrib><creatorcontrib>Ma, Anna</creatorcontrib><creatorcontrib>Cohen, Sarah Beaussant</creatorcontrib><creatorcontrib>Maziarz, Richard T.</creatorcontrib><creatorcontrib>Bachier, Carlos</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McGuirk, Joseph P.</au><au>Tam, Constantine S.</au><au>Kröger, Nicolaus</au><au>Riedell, Peter A.</au><au>Murthy, Hemant S.</au><au>Ho, Phoebe Joy</au><au>Maakaron, Joseph E.</au><au>Waller, Edmund K.</au><au>Awan, Farrukh T.</au><au>Shaughnessy, Paul J.</au><au>Ghobadi, Armin</au><au>Bishop, Michael R.</au><au>Alfonso-Pierola, Ana</au><au>Dickinson, Michael</au><au>Ramakrishnan Geethakumari, Praveen</au><au>Ross, Ainsley</au><au>Stevens, William</au><au>Xu, Huansheng</au><au>Ma, Anna</au><au>Cohen, Sarah Beaussant</au><au>Maziarz, Richard T.</au><au>Bachier, Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>10303</spage><epage>10306</epage><pages>10303-10306</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-166432</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.10303-10306 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_166432 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T21%3A34%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CTX110%20Allogeneic%20CRISPR-Cas9-Engineered%20CAR%20T%20Cells%20in%20Patients%20(Pts)%20with%20Relapsed%20or%20Refractory%20(R/R)%20Large%20B-Cell%20Lymphoma%20(LBCL):%20Results%20from%20the%20Phase%201%20Dose%20Escalation%20Carbon%20Study&rft.jtitle=Blood&rft.au=McGuirk,%20Joseph%20P.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=10303&rft.epage=10306&rft.pages=10303-10306&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-166432&rft_dat=%3Celsevier_cross%3ES0006497122061900%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122061900&rfr_iscdi=true |